Short answer
TriSalus Life Sciences, Inc. (TLSI) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026 announced.
TriSalus Life Sciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026 announced
- Full operating and financial details contained in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $12.9M, up 11.3% YoY, signaling continued TriNav adoption despite slower-than-expected salesforce productivity
- Gross margin expanded to 86.2% from 83.5%, while operating loss narrowed to $7.7M from $9.0M
- 2026 revenue guidance reset to $46M-$48M, implying 2%-6% growth and a more measured near-term outlook
- CMS reimbursement materially improves January 2027: C8004 payment rises to approximately $20,910 from $11,794
- CMS also established approximately $13,800 office-based-lab payment for PEDD, broadening 2027 commercialization potential
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TriSalus Life Sciences, Inc. 8-K filings
Get the next TLSI 8-K as it lands
Follow TLSI for push alerts, or ask the research agent what this filing means.